AAPL315.62-0.60 (-0.19%) ▼|ABBV250.37+1.59 (+0.64%) ▲|ABT105.40-0.12 (-0.11%) ▼|ACN177.31-1.72 (-0.96%) ▼|ADBE255.49-1.78 (-0.69%) ▼|AMAT467.78-5.01 (-1.06%) ▼|AMD519.22+13.48 (+2.67%) ▲|AMGN392.11-1.07 (-0.27%) ▼|AMT175.37-0.37 (-0.21%) ▼|AMZN252.15-4.83 (-1.88%) ▼|AVGO363.76-4.81 (-1.30%) ▼|AXP322.54-3.57 (-1.09%) ▼|BA208.00-2.73 (-1.30%) ▼|BAC62.90+0.51 (+0.81%) ▲|BKNG173.08-7.23 (-4.01%) ▼|BLK1,075.34-20.04 (-1.83%) ▼|BMY64.31-0.39 (-0.60%) ▼|BNY163.26+0.41 (+0.25%) ▲|BRK-B507.31+1.48 (+0.29%) ▲|C138.43+1.69 (+1.23%) ▲|CAT818.05-4.43 (-0.54%) ▼|CL88.02-0.39 (-0.44%) ▼|CMCSA24.56-1.77 (-6.72%) ▼|COF212.55-1.42 (-0.66%) ▼|COP137.24+2.20 (+1.63%) ▲|COST901.49-8.69 (-0.95%) ▼|CRM244.28-4.85 (-1.94%) ▼|CSCO109.28+0.11 (+0.10%) ▲|CVS95.82-0.25 (-0.26%) ▼|CVX214.01+4.21 (+2.01%) ▲|DE677.21-3.53 (-0.52%) ▼|DHR205.08-0.15 (-0.07%) ▼|DIS104.43-0.63 (-0.60%) ▼|DUK120.32-0.92 (-0.76%) ▼|EMR151.08-1.07 (-0.70%) ▼|FDX310.14-3.99 (-1.27%) ▼|GD352.72-3.87 (-1.08%) ▼|GE326.49-8.42 (-2.52%) ▼|GEV953.40-17.91 (-1.84%) ▼|GILD145.74-0.90 (-0.61%) ▼|GM84.75-1.04 (-1.21%) ▼|GOOG328.54-6.85 (-2.04%) ▼|GOOGL330.99-7.38 (-2.18%) ▼|GS1,031.66-4.87 (-0.47%) ▼|HD311.17-2.53 (-0.81%) ▼|HON205.26-2.98 (-1.43%) ▼|IBM239.46+7.37 (+3.18%) ▲|INTC106.23+1.76 (+1.68%) ▲|INTU314.34-4.59 (-1.44%) ▼|ISRG352.63+2.47 (+0.71%) ▲|JNJ267.95-1.17 (-0.43%) ▼|JPM355.39+1.88 (+0.53%) ▲|KO87.79-0.58 (-0.65%) ▼|LIN466.02-2.36 (-0.50%) ▼|LLY1,125.26+1.35 (+0.12%) ▲|LMT526.31-9.84 (-1.84%) ▼|LOW198.71-2.09 (-1.04%) ▼|LRCX314.93-5.50 (-1.71%) ▼|MA569.83-1.06 (-0.19%) ▼|MCD254.55-1.26 (-0.49%) ▼|MDLZ62.28+0.65 (+1.05%) ▲|MDT92.07-0.32 (-0.35%) ▼|META655.08+41.60 (+6.78%) ▲|MMM164.39-3.13 (-1.87%) ▼|MO67.83-0.34 (-0.50%) ▼|MRK147.81-0.65 (-0.44%) ▼|MS215.92-0.32 (-0.15%) ▼|MSFT491.59-2.37 (-0.48%) ▼|MU1,029.05+28.79 (+2.88%) ▲|NEE83.08-0.76 (-0.90%) ▼|NFLX76.13-0.64 (-0.83%) ▼|NKE37.26-0.85 (-2.22%) ▼|NOW131.85-2.36 (-1.76%) ▼|NVDA223.79-1.94 (-0.86%) ▼|ORCL162.64+0.12 (+0.07%) ▲|PEP137.14-1.31 (-0.94%) ▼|PFE27.81+0.02 (+0.07%) ▲|PG142.74-2.84 (-1.95%) ▼|PLTR170.33+0.03 (+0.01%) ▲|PM185.58+0.85 (+0.46%) ▲|QCOM175.42+1.33 (+0.76%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO608.81+5.79 (+0.96%) ▲|TMUS177.96-3.73 (-2.05%) ▼|TSLA369.13+0.97 (+0.26%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|AAPL315.62-0.60 (-0.19%) ▼|ABBV250.37+1.59 (+0.64%) ▲|ABT105.40-0.12 (-0.11%) ▼|ACN177.31-1.72 (-0.96%) ▼|ADBE255.49-1.78 (-0.69%) ▼|AMAT467.78-5.01 (-1.06%) ▼|AMD519.22+13.48 (+2.67%) ▲|AMGN392.11-1.07 (-0.27%) ▼|AMT175.37-0.37 (-0.21%) ▼|AMZN252.15-4.83 (-1.88%) ▼|AVGO363.76-4.81 (-1.30%) ▼|AXP322.54-3.57 (-1.09%) ▼|BA208.00-2.73 (-1.30%) ▼|BAC62.90+0.51 (+0.81%) ▲|BKNG173.08-7.23 (-4.01%) ▼|BLK1,075.34-20.04 (-1.83%) ▼|BMY64.31-0.39 (-0.60%) ▼|BNY163.26+0.41 (+0.25%) ▲|BRK-B507.31+1.48 (+0.29%) ▲|C138.43+1.69 (+1.23%) ▲|CAT818.05-4.43 (-0.54%) ▼|CL88.02-0.39 (-0.44%) ▼|CMCSA24.56-1.77 (-6.72%) ▼|COF212.55-1.42 (-0.66%) ▼|COP137.24+2.20 (+1.63%) ▲|COST901.49-8.69 (-0.95%) ▼|CRM244.28-4.85 (-1.94%) ▼|CSCO109.28+0.11 (+0.10%) ▲|CVS95.82-0.25 (-0.26%) ▼|CVX214.01+4.21 (+2.01%) ▲|DE677.21-3.53 (-0.52%) ▼|DHR205.08-0.15 (-0.07%) ▼|DIS104.43-0.63 (-0.60%) ▼|DUK120.32-0.92 (-0.76%) ▼|EMR151.08-1.07 (-0.70%) ▼|FDX310.14-3.99 (-1.27%) ▼|GD352.72-3.87 (-1.08%) ▼|GE326.49-8.42 (-2.52%) ▼|GEV953.40-17.91 (-1.84%) ▼|GILD145.74-0.90 (-0.61%) ▼|GM84.75-1.04 (-1.21%) ▼|GOOG328.54-6.85 (-2.04%) ▼|GOOGL330.99-7.38 (-2.18%) ▼|GS1,031.66-4.87 (-0.47%) ▼|HD311.17-2.53 (-0.81%) ▼|HON205.26-2.98 (-1.43%) ▼|IBM239.46+7.37 (+3.18%) ▲|INTC106.23+1.76 (+1.68%) ▲|INTU314.34-4.59 (-1.44%) ▼|ISRG352.63+2.47 (+0.71%) ▲|JNJ267.95-1.17 (-0.43%) ▼|JPM355.39+1.88 (+0.53%) ▲|KO87.79-0.58 (-0.65%) ▼|LIN466.02-2.36 (-0.50%) ▼|LLY1,125.26+1.35 (+0.12%) ▲|LMT526.31-9.84 (-1.84%) ▼|LOW198.71-2.09 (-1.04%) ▼|LRCX314.93-5.50 (-1.71%) ▼|MA569.83-1.06 (-0.19%) ▼|MCD254.55-1.26 (-0.49%) ▼|MDLZ62.28+0.65 (+1.05%) ▲|MDT92.07-0.32 (-0.35%) ▼|META655.08+41.60 (+6.78%) ▲|MMM164.39-3.13 (-1.87%) ▼|MO67.83-0.34 (-0.50%) ▼|MRK147.81-0.65 (-0.44%) ▼|MS215.92-0.32 (-0.15%) ▼|MSFT491.59-2.37 (-0.48%) ▼|MU1,029.05+28.79 (+2.88%) ▲|NEE83.08-0.76 (-0.90%) ▼|NFLX76.13-0.64 (-0.83%) ▼|NKE37.26-0.85 (-2.22%) ▼|NOW131.85-2.36 (-1.76%) ▼|NVDA223.79-1.94 (-0.86%) ▼|ORCL162.64+0.12 (+0.07%) ▲|PEP137.14-1.31 (-0.94%) ▼|PFE27.81+0.02 (+0.07%) ▲|PG142.74-2.84 (-1.95%) ▼|PLTR170.33+0.03 (+0.01%) ▲|PM185.58+0.85 (+0.46%) ▲|QCOM175.42+1.33 (+0.76%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO608.81+5.79 (+0.96%) ▲|TMUS177.96-3.73 (-2.05%) ▼|TSLA369.13+0.97 (+0.26%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|
28.6 C
New York
Wednesday, September 9, 2026

Tag: biopharmaceutical

newssourceFORcompanyinformationcontent1releasesmarket

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE®), and the tests for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.

Fortrea Reports Second Quarter 2025 Results

For the three months ended June 30, 2025, from continuing operations:

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST.

Cryoport Reports Second Quarter 2025 Financial Results

Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose...

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.

Cell Line and Membrane Market to Grow at 12.5% CAGR Through 2030

"Market Analysis Highlights Growth Potential, Emerging Technologies, ESG Trends, and Strategic Insights in the Cell Line and Membrane Sector" BOSTON, Aug. 5, 2025 /PRNewswire/ --...

New Jersey Innovation Institute Appoints Chrissy Buteas and Elisa Charters

NEWARK, N.J., Aug. 5, 2025 /PRNewswire/ -- New Jersey Innovation Institute (NJII), a subsidiary of the New Jersey Institute of Technology (NJIT), is pleased...

Cell Culture Market to Reach USD 71.1 Billion by 2032, Says SkyQuest Technology Consulting

The cell culture market is anticipated to expand at a rapid pace owing to growing innovations in biotechnologies, and biopharmaceuticals on the back of...

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST.

METiS Technologies Closes RMB 400 Million Series D Financing to Power Beijing’s Biopharmaceutical Innovation Engine

BEIJING, China, Aug. 4, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB...

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiopharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers